Nucleocapsid Serum Antigen Determination in SARS-CoV-2 Infected Patients Using the Single Molecule Array Technology and Prediction of Disease Severity
Journal of Infection | January 21, 2022
Favresse J, Bayart J-L, David C, Dogné J-M and Douxfils J
Journal of Infection
To the Editor,We read with interest the paper of Li et al. reporting serum amyloid A (SAA) as a possible biomarker to evaluate the severity of coronavirus disease and progression. (1) They found that the ratio of SAA to lymphocyte (SAA/L) was significantly increased in critically severe patients. A recent meta-analysis also supports the use of this biomarker to assess the severity of the disease although a high heterogeneity among the studies was reported. (2) Other biomarkers have also been linked with disease severity and complications and we would like to share our data regarding the association between the level of SARS-CoV-2 nucleocapsid antigens and the severity of COVID-19.
Share this page